CytomX Therapeutics Stock Price, News & Analysis (NASDAQ:CTMX)

$29.22 +0.62 (+2.17 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$29.22
Today's Range$28.02 - $29.26
52-Week Range$11.49 - $29.26
Volume219,115 shs
Average Volume299,423 shs
Market Capitalization$1.15 billion
P/E Ratio-18.61
Dividend YieldN/A
BetaN/A

About CytomX Therapeutics (NASDAQ:CTMX)

CytomX Therapeutics logoCytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies. Its investigational Probody therapeutics address clinically validated cancer targets in immuno-oncology, such as programmed death-ligand 1, against which CX-072 is directed, as well as targets, such as cluster of differentiation 166, against, which CX-2009 is directed.

Receive CTMX News and Ratings via Email

Sign-up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:CTMX
CUSIPN/A
Phone+1-650-5153185

Debt

Debt-to-Equity RatioN/A
Current Ratio5.28%
Quick Ratio5.28%

Price-To-Earnings

Trailing P/E Ratio-18.6114649681529
Forward P/E Ratio-18.49
P/E GrowthN/A

Sales & Book Value

Annual Sales$15.04 million
Price / Sales74.62
Cash FlowN/A
Price / CashN/A
Book Value$2.16 per share
Price / Book13.53

Profitability

Trailing EPS($1.57)
Net Income$-58,900,000.00
Net Margins-113.64%
Return on Equity-92.42%
Return on Assets-20.70%

Miscellaneous

Employees80
Outstanding Shares38,410,000

CytomX Therapeutics (NASDAQ:CTMX) Frequently Asked Questions

What is CytomX Therapeutics' stock symbol?

CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."

How were CytomX Therapeutics' earnings last quarter?

CytomX Therapeutics Inc (NASDAQ:CTMX) released its quarterly earnings data on Thursday, November, 3rd. The biotechnology company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by $0.05. The biotechnology company earned $3.45 million during the quarter, compared to analysts' expectations of $3.20 million. CytomX Therapeutics had a negative return on equity of 92.42% and a negative net margin of 113.64%. View CytomX Therapeutics' Earnings History.

When will CytomX Therapeutics make its next earnings announcement?

CytomX Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 7th 2018. View Earnings Estimates for CytomX Therapeutics.

Where is CytomX Therapeutics' stock going? Where will CytomX Therapeutics' stock price be in 2018?

11 analysts have issued 12 month price objectives for CytomX Therapeutics' shares. Their forecasts range from $24.00 to $44.00. On average, they expect CytomX Therapeutics' share price to reach $33.88 in the next twelve months. View Analyst Ratings for CytomX Therapeutics.

What are Wall Street analysts saying about CytomX Therapeutics stock?

Here are some recent quotes from research analysts about CytomX Therapeutics stock:

  • 1. According to Zacks Investment Research, "CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California. " (2/19/2018)
  • 2. Cann analysts commented, "Loss per share was $0.69, compared to our estimate of $0.56. This was the result of higher than expected R&D expense of $28.1 million compared to our estimate of $15.2 million, which resulted from a $10 million payment to UCSB for a sublicense payment. This was partially offset by higher than estimated revenue of $8.8 million compared to our estimated $1.0 million." (8/8/2017)
  • 3. Cowen Inc analysts commented, "CTMX announced that the first patient in CX-2009’s (CD166 PDC) Phase I trial has." (6/28/2017)
  • 4. HC Wainwright analysts commented, "Before the market opened on May 5, TG reported 1Q17 results. The company recently reported preliminary data from its ongoing Phase II study of TG-1101 in patients with relapsing forms of multiple sclerosis. Preliminary results indicated that TG-1101 was well tolerated with no Grade III/IV adverse events (AEs) observed and the most commonly reported AE being infusion-related reactions, with median time on study of five months. All patients achieved the primary endpoint of greater than 95% B-cell depletion by four weeks. The median B-cell depletion at week four was reported to be 99% after two infusions with a cumulative dose of 600 mg, which compares favorably to other anti-CD20 monoclonal antibodies (mAbs). Management indicated that additional data from the ongoing Phase II study will be reported later this year and that the company is on track to initiate a Phase III trial in MS in 2H17." (5/8/2017)

Who are some of CytomX Therapeutics' key competitors?

Who are CytomX Therapeutics' key executives?

CytomX Therapeutics' management team includes the folowing people:

  • Hoyoung Huh Ph.D., Chairman of the Board (Age 48)
  • Sean A. McCarthy Ph.D., President, Chief Executive Officer, Director (Age 50)
  • Debanjan Ray, Chief Financial Officer, , IR Contact Officer (Age 39)
  • Cynthia Jane Ladd, Senior Vice President, General Counsel (Age 62)
  • W. Michael Kavanaugh M.D., Chief Scientific Officer and Head - Research and Non-Clinical Development (Age 60)
  • Rachel W. Humphrey M.D., Chief Medical Officer (Age 55)
  • Charles S. Fuchs M.D., Director
  • Marion McCourt, Director (Age 57)
  • John A. Scarlett M.D., Director (Age 66)
  • Frederick Gluck, Independent Director (Age 81)

Who owns CytomX Therapeutics stock?

CytomX Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.89%), Perceptive Advisors LLC (6.48%), BVF Inc. IL (2.93%), Millennium Management LLC (2.18%), Renaissance Technologies LLC (1.86%) and Goldman Sachs Group Inc. (1.19%). Company insiders that own CytomX Therapeutics stock include Debanjan Ray, Frederick W Gluck, Ix LP Canaan, Kevin P Starr, Robert C Goeltz II, Robert I Tepper, Rock Ventures Lp Third, Sean A Mccarthy, Timothy M Shannon and William Michael Kavanaugh. View Institutional Ownership Trends for CytomX Therapeutics.

Who sold CytomX Therapeutics stock? Who is selling CytomX Therapeutics stock?

CytomX Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Tekla Capital Management LLC, Deutsche Bank AG, Candriam Luxembourg S.C.A., Sphera Funds Management LTD., Foundry Partners LLC, Vident Investment Advisory LLC and TIAA CREF Investment Management LLC. Company insiders that have sold CytomX Therapeutics company stock in the last year include Debanjan Ray, Frederick W Gluck, Kevin P Starr, Robert C Goeltz II, Robert I Tepper, Rock Ventures Lp Third, Sean A Mccarthy and William Michael Kavanaugh. View Insider Buying and Selling for CytomX Therapeutics.

Who bought CytomX Therapeutics stock? Who is buying CytomX Therapeutics stock?

CytomX Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, BlackRock Inc., Millennium Management LLC, Nexthera Capital LP, Renaissance Technologies LLC, American Century Companies Inc., Goldman Sachs Group Inc. and Wells Fargo & Company MN. View Insider Buying and Selling for CytomX Therapeutics.

How do I buy CytomX Therapeutics stock?

Shares of CytomX Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CytomX Therapeutics' stock price today?

One share of CytomX Therapeutics stock can currently be purchased for approximately $29.22.

How big of a company is CytomX Therapeutics?

CytomX Therapeutics has a market capitalization of $1.15 billion and generates $15.04 million in revenue each year. The biotechnology company earns $-58,900,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis. CytomX Therapeutics employs 80 workers across the globe.

How can I contact CytomX Therapeutics?

CytomX Therapeutics' mailing address is 151 Oyster Point Blvd Ste 400, SOUTH SAN FRANCISCO, CA 94080-1910, United States. The biotechnology company can be reached via phone at +1-650-5153185 or via email at [email protected]


MarketBeat Community Rating for CytomX Therapeutics (CTMX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  167 (Vote Outperform)
Underperform Votes:  122 (Vote Underperform)
Total Votes:  289
MarketBeat's community ratings are surveys of what our community members think about CytomX Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

CytomX Therapeutics (NASDAQ:CTMX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.642.642.602.50
Ratings Breakdown: 1 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $33.88$33.88$33.00$27.75
Price Target Upside: 48.12% upside48.12% upside64.67% upside73.87% upside

CytomX Therapeutics (NASDAQ:CTMX) Consensus Price Target History

Price Target History for CytomX Therapeutics (NASDAQ:CTMX)

CytomX Therapeutics (NASDAQ:CTMX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/5/2018CitigroupInitiated CoverageBuy -> Buy$40.00HighView Rating Details
10/23/2017Cantor FitzgeraldInitiated CoverageOverweight$35.00N/AView Rating Details
10/5/2017CowenReiterated RatingOutperformN/AView Rating Details
10/4/2017OppenheimerReiterated RatingHoldHighView Rating Details
10/4/2017Bank of AmericaBoost Price TargetBuy$30.00 -> $34.00HighView Rating Details
10/4/2017NomuraBoost Price TargetBuy$44.00HighView Rating Details
10/4/2017WedbushSet Price TargetBuy$26.00 -> $37.00HighView Rating Details
8/25/2017Jefferies GroupSet Price TargetBuy$25.00LowView Rating Details
8/8/2017CannReiterated RatingHoldHighView Rating Details
5/8/2017HC WainwrightReiterated RatingBuyLowView Rating Details
3/20/2017InstinetBoost Price TargetSell$21.00 -> $32.00MediumView Rating Details
(Data available from 2/24/2016 forward)

Earnings

CytomX Therapeutics (NASDAQ:CTMX) Earnings History and Estimates Chart

Earnings by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

CytomX Therapeutics (NASDAQ CTMX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2018($0.46)N/AView Earnings Details
11/7/2017Q3 2017($0.14)($0.28)$16.60 million$24.14 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.39)($0.69)$4.95 million$8.75 millionViewListenView Earnings Details
5/5/2017Q1 2017($0.55)($0.23)$2.10 million$11.65 millionViewN/AView Earnings Details
3/2/2017Q4 2016($0.45)($0.39)$6.27 millionViewN/AView Earnings Details
11/3/2016Q3($0.35)($0.40)$3.20 million$3.45 millionViewN/AView Earnings Details
8/3/2016Q2($0.41)($0.39)$2.10 million$3.09 millionViewN/AView Earnings Details
5/6/2016Q1 2016($0.26)($0.44)$6.00 million$2.22 millionViewN/AView Earnings Details
3/7/2016Q4 2015($0.34)($0.39)$1.75 million$1.99 millionViewN/AView Earnings Details
11/23/2015Q3 2015($0.25)($14.26)$1.75 million$1.94 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

CytomX Therapeutics (NASDAQ:CTMX) Earnings Estimates

2018 EPS Consensus Estimate: ($0.73)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.22)($0.01)($0.12)
Q2 20182($0.25)($0.08)($0.17)
Q3 20182($0.28)($0.14)($0.21)
Q4 20182($0.30)($0.18)($0.24)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for CytomX Therapeutics (NASDAQ:CTMX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

CytomX Therapeutics (NASDAQ CTMX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.70%
Institutional Ownership Percentage: 75.31%
Insider Trades by Quarter for CytomX Therapeutics (NASDAQ:CTMX)
Institutional Ownership by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

CytomX Therapeutics (NASDAQ CTMX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/1/2018Debanjan RayCFOSell2,548$26.69$68,006.124,741View SEC Filing  
1/5/2018Frederick W GluckDirectorSell10,000$25.01$250,100.00View SEC Filing  
1/5/2018Sean A MccarthyInsiderSell6,526$25.01$163,215.2611,169View SEC Filing  
1/2/2018Debanjan RayCFOSell2,500$21.11$52,775.00View SEC Filing  
1/2/2018Sean A MccarthyInsiderSell13,052$21.04$274,614.0817,695View SEC Filing  
12/26/2017Frederick W GluckDirectorSell5,000$22.29$111,450.00View SEC Filing  
12/1/2017Debanjan RayCFOSell2,500$20.58$51,450.00View SEC Filing  
12/1/2017Sean A MccarthyInsiderSell14,340$20.60$295,404.00View SEC Filing  
11/1/2017Debanjan RayCFOSell2,500$20.00$50,000.0012,126View SEC Filing  
11/1/2017Sean A MccarthyCEOSell14,342$19.86$284,832.1218,587View SEC Filing  
10/4/2017Frederick W GluckDirectorSell10,000$24.27$242,700.00View SEC Filing  
10/4/2017Robert I TepperMajor ShareholderSell24,777$24.34$603,072.18View SEC Filing  
10/4/2017Sean A MccarthyCEOSell19,120$24.13$461,365.6023,365View SEC Filing  
10/4/2017William Michael KavanaughInsiderSell48,368$24.34$1,177,277.12View SEC Filing  
10/2/2017Debanjan RayCFOSell2,500$18.10$45,250.00View SEC Filing  
10/2/2017Sean A MccarthyInsiderSell9,562$18.57$177,566.34View SEC Filing  
9/26/2017Frederick W GluckDirectorSell5,000$17.30$86,500.00View SEC Filing  
9/19/2017Robert I TepperMajor ShareholderSell20,000$18.00$360,000.0054,293View SEC Filing  
9/1/2017Debanjan RayCFOSell2,500$17.17$42,925.0017,126View SEC Filing  
9/1/2017Sean A MccarthyInsiderSell9,930$17.32$171,987.6014,175View SEC Filing  
8/31/2017Sean A MccarthyInsiderSell18,756$17.50$328,230.0023,001View SEC Filing  
8/9/2017Debanjan RayCFOSell2,500$15.00$37,500.0019,626View SEC Filing  
8/9/2017Sean A MccarthyInsiderSell4,781$15.00$71,715.009,026View SEC Filing  
7/3/2017Debanjan RayCFOSell2,500$15.47$38,675.0022,126View SEC Filing  
7/3/2017Sean A MccarthyInsiderSell4,781$15.52$74,201.129,026View SEC Filing  
6/29/2017Robert I TepperMajor ShareholderSell15,000$16.00$240,000.0044,777View SEC Filing  
6/26/2017Frederick W GluckDirectorSell5,000$14.61$73,050.00View SEC Filing  
6/26/2017Sean A MccarthyInsiderSell4,481$15.00$67,215.008,726View SEC Filing  
6/5/2017Sean A MccarthyInsiderSell300$15.00$4,500.004,545View SEC Filing  
5/1/2017Sean A MccarthyInsiderSell4,781$15.70$75,061.706,760View SEC Filing  
4/12/2017Kevin P StarrMajor ShareholderSell28,357$16.36$463,920.5231,419View SEC Filing  
4/4/2017Sean A MccarthyInsiderSell9,562$17.22$164,657.646,760View SEC Filing  
3/27/2017Rock Ventures Lp ThirdMajor ShareholderSell1,650,000$17.39$28,693,500.00View SEC Filing  
3/20/2017Robert C Goeltz IICFOSell21,517$19.81$426,251.7731,306View SEC Filing  
3/20/2017Sean A MccarthyInsiderSell14,343$19.60$281,122.8016,322View SEC Filing  
3/3/2017Sean A MccarthyInsiderSell14,343$15.00$215,145.0016,322View SEC Filing  
11/28/2016Ix L.P. CanaanDirectorSell38,459$11.56$444,586.04View SEC Filing  
11/22/2016Ix L.P. CanaanDirectorSell42,550$11.71$498,260.50View SEC Filing  
11/21/2016Ix L.P. CanaanDirectorSell45,324$11.61$526,211.64View SEC Filing  
11/16/2016Ix L.P. CanaanDirectorSell51,581$11.50$593,181.50View SEC Filing  
11/15/2016Timothy M ShannonDirectorSell33,064$11.48$379,574.72268View SEC Filing  
11/14/2016Ix L.P. CanaanDirectorSell86,270$11.16$962,773.20View SEC Filing  
11/9/2016Ix L.P. CanaanDirectorSell13,730$11.03$151,441.90View SEC Filing  
6/10/2016Timothy M ShannonDirectorSell48,427$10.07$487,659.89134View SEC Filing  
6/7/2016Ix L.P. CanaanDirectorSell111,498$10.01$1,116,094.98View SEC Filing  
6/3/2016Ix L.P. CanaanDirectorSell59,621$10.80$643,906.80View SEC Filing  
6/1/2016Ix L.P. CanaanDirectorSell22,463$10.75$241,477.25View SEC Filing  
5/27/2016Ix L.P. CanaanDirectorSell25,082$10.60$265,869.20View SEC Filing  
5/26/2016Timothy M ShannonDirectorSell51,343$10.34$530,886.62134View SEC Filing  
5/24/2016Ix L.P. CanaanDirectorSell13,253$10.09$133,722.77View SEC Filing  
5/20/2016Ix L.P. CanaanDirectorSell8,687$10.10$87,738.70View SEC Filing  
10/14/2015Cynthia J LaddVPBuy3,000$12.00$36,000.003,000View SEC Filing  
10/14/2015Frederick W GluckDirectorBuy15,000$12.00$180,000.00147,791View SEC Filing  
10/14/2015James E FlynnInsiderBuy625,000$12.00$7,500,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

CytomX Therapeutics (NASDAQ CTMX) News Headlines

Source:
DateHeadline
CytomX Therapeutics to Announce Full-Year 2017 Financial Results and Host Operational Update Webcast ... - GlobeNewswire (press release)CytomX Therapeutics to Announce Full-Year 2017 Financial Results and Host Operational Update Webcast ... - GlobeNewswire (press release)
globenewswire.com - February 23 at 8:18 AM
$10.70 Million in Sales Expected for CytomX Therapeutics Inc (CTMX) This Quarter$10.70 Million in Sales Expected for CytomX Therapeutics Inc (CTMX) This Quarter
www.americanbankingnews.com - February 23 at 1:06 AM
CytomX Therapeutics to Announce Full-Year 2017 Financial Results and Host Operational Update Webcast Conference CallCytomX Therapeutics to Announce Full-Year 2017 Financial Results and Host Operational Update Webcast Conference Call
finance.yahoo.com - February 22 at 5:39 PM
CytomX Therapeutics Inc (CTMX) Receives Average Rating of "Buy" from BrokeragesCytomX Therapeutics Inc (CTMX) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - February 21 at 7:30 PM
CytomX Therapeutics (CTMX) Lowered to "Sell" at Zacks Investment ResearchCytomX Therapeutics (CTMX) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - February 19 at 9:08 PM
Zacks Investment Research Lowers CytomX Therapeutics (CTMX) to SellZacks Investment Research Lowers CytomX Therapeutics (CTMX) to Sell
www.americanbankingnews.com - February 12 at 10:12 PM
CytomX Therapeutics (CTMX) Rating Lowered to Sell at Zacks Investment ResearchCytomX Therapeutics (CTMX) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - February 5 at 9:16 PM
 Analysts Anticipate CytomX Therapeutics Inc (CTMX) Will Post Earnings of -$0.39 Per Share Analysts Anticipate CytomX Therapeutics Inc (CTMX) Will Post Earnings of -$0.39 Per Share
www.americanbankingnews.com - February 4 at 9:06 PM
Insider Selling: CytomX Therapeutics Inc (CTMX) CFO Sells 2,548 Shares of StockInsider Selling: CytomX Therapeutics Inc (CTMX) CFO Sells 2,548 Shares of Stock
www.americanbankingnews.com - February 2 at 10:02 PM
CytomX Therapeutics Inc (CTMX) Receives Consensus Recommendation of "Hold" from BrokeragesCytomX Therapeutics Inc (CTMX) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 27 at 7:30 PM
CytomX Therapeutics (CTMX) Downgraded to "Sell" at Zacks Investment ResearchCytomX Therapeutics (CTMX) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - January 24 at 8:00 PM
CytomX Therapeutics Inc (CTMX) Expected to Post Quarterly Sales of $10.70 MillionCytomX Therapeutics Inc (CTMX) Expected to Post Quarterly Sales of $10.70 Million
www.americanbankingnews.com - January 20 at 1:52 AM
Head-To-Head Comparison: Dova Pharmaceuticals (DOVA) versus CytomX Therapeutics (CTMX)Head-To-Head Comparison: Dova Pharmaceuticals (DOVA) versus CytomX Therapeutics (CTMX)
www.americanbankingnews.com - January 18 at 1:08 AM
Short Interest in CytomX Therapeutics Inc (CTMX) Expands By 36.3%Short Interest in CytomX Therapeutics Inc (CTMX) Expands By 36.3%
www.americanbankingnews.com - January 14 at 2:32 AM
Sean A. Mccarthy Sells 6,526 Shares of CytomX Therapeutics, Inc. (CTMX) StockSean A. Mccarthy Sells 6,526 Shares of CytomX Therapeutics, Inc. (CTMX) Stock
www.americanbankingnews.com - January 9 at 3:32 PM
Insider Selling: CytomX Therapeutics, Inc. (CTMX) Director Sells 10,000 Shares of StockInsider Selling: CytomX Therapeutics, Inc. (CTMX) Director Sells 10,000 Shares of Stock
www.americanbankingnews.com - January 8 at 7:28 PM
CytomX Therapeutics (CTMX) Now Covered by CitigroupCytomX Therapeutics (CTMX) Now Covered by Citigroup
www.americanbankingnews.com - January 5 at 6:28 PM
Insider Selling: CytomX Therapeutics, Inc. (CTMX) Insider Sells 13,052 Shares of StockInsider Selling: CytomX Therapeutics, Inc. (CTMX) Insider Sells 13,052 Shares of Stock
www.americanbankingnews.com - January 4 at 3:36 PM
CytomX Therapeutics, Inc. (CTMX) Expected to Post Quarterly Sales of $10.70 MillionCytomX Therapeutics, Inc. (CTMX) Expected to Post Quarterly Sales of $10.70 Million
www.americanbankingnews.com - January 4 at 3:00 PM
CytomX Therapeutics (CTMX) and Galmed Pharmaceuticals (GLMD) Financial ReviewCytomX Therapeutics (CTMX) and Galmed Pharmaceuticals (GLMD) Financial Review
www.americanbankingnews.com - January 4 at 9:56 AM
Head-To-Head Review: CytomX Therapeutics (CTMX) versus Its CompetitorsHead-To-Head Review: CytomX Therapeutics (CTMX) versus Its Competitors
www.americanbankingnews.com - January 4 at 7:58 AM
Debanjan Ray Sells 2,500 Shares of CytomX Therapeutics, Inc. (CTMX) StockDebanjan Ray Sells 2,500 Shares of CytomX Therapeutics, Inc. (CTMX) Stock
www.americanbankingnews.com - January 3 at 7:54 PM
CytomX Therapeutics, Inc. (CTMX) Receives Average Recommendation of "Hold" from BrokeragesCytomX Therapeutics, Inc. (CTMX) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 2 at 7:44 PM
Financial Comparison: CytomX Therapeutics (CTMX) and Its RivalsFinancial Comparison: CytomX Therapeutics (CTMX) and Its Rivals
www.americanbankingnews.com - January 2 at 9:32 AM
Frederick W. Gluck Sells 5,000 Shares of CytomX Therapeutics, Inc. (CTMX) StockFrederick W. Gluck Sells 5,000 Shares of CytomX Therapeutics, Inc. (CTMX) Stock
www.americanbankingnews.com - December 28 at 6:58 PM
Financial Comparison: CytomX Therapeutics (CTMX) versus Its CompetitorsFinancial Comparison: CytomX Therapeutics (CTMX) versus Its Competitors
www.americanbankingnews.com - December 27 at 9:58 AM
ETFs with exposure to CytomX Therapeutics, Inc. : December 19, 2017ETFs with exposure to CytomX Therapeutics, Inc. : December 19, 2017
finance.yahoo.com - December 19 at 5:26 PM
Head-To-Head Comparison: CytomX Therapeutics (CTMX) versus Its CompetitorsHead-To-Head Comparison: CytomX Therapeutics (CTMX) versus Its Competitors
www.americanbankingnews.com - December 19 at 1:26 AM
Analyzing CytomX Therapeutics (CTMX) and Its PeersAnalyzing CytomX Therapeutics (CTMX) and Its Peers
www.americanbankingnews.com - December 18 at 11:08 PM
 Brokerages Expect CytomX Therapeutics, Inc. (CTMX) Will Post Quarterly Sales of $10.70 Million Brokerages Expect CytomX Therapeutics, Inc. (CTMX) Will Post Quarterly Sales of $10.70 Million
www.americanbankingnews.com - December 18 at 4:16 PM
CytomX Therapeutics Added to NASDAQ Biotechnology IndexCytomX Therapeutics Added to NASDAQ Biotechnology Index
finance.yahoo.com - December 18 at 9:34 AM
CytomX Therapeutics (CTMX) Upgraded at BidaskClubCytomX Therapeutics (CTMX) Upgraded at BidaskClub
www.americanbankingnews.com - December 16 at 2:52 PM
Wedbush Is Out With Top Stock Picks for 2018Wedbush Is Out With Top Stock Picks for 2018
247wallst.com - December 13 at 5:38 PM
BidaskClub Lowers CytomX Therapeutics (CTMX) to HoldBidaskClub Lowers CytomX Therapeutics (CTMX) to Hold
www.americanbankingnews.com - December 9 at 6:32 PM
CytomX Therapeutics, Inc. (CTMX) Receives Average Rating of "Hold" from BrokeragesCytomX Therapeutics, Inc. (CTMX) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - December 8 at 9:38 PM
Sean A. Mccarthy Sells 14,340 Shares of CytomX Therapeutics, Inc. (CTMX) StockSean A. Mccarthy Sells 14,340 Shares of CytomX Therapeutics, Inc. (CTMX) Stock
www.americanbankingnews.com - December 5 at 6:48 PM
CytomX Therapeutics (CTMX) Downgraded by ValuEngineCytomX Therapeutics (CTMX) Downgraded by ValuEngine
www.americanbankingnews.com - December 3 at 5:54 PM
Peninsula drug makers Son of Yervoy dares cancer to pull off its maskPeninsula drug maker's Son of Yervoy dares cancer to pull off its mask
www.bizjournals.com - November 30 at 9:30 AM
CytomX Therapeutics Announces FDA Acceptance of Investigational New Drug Application for CTLA-4 Probody TherapeuticCytomX Therapeutics Announces FDA Acceptance of Investigational New Drug Application for CTLA-4 Probody Therapeutic
finance.yahoo.com - November 28 at 8:36 AM
-$0.39 Earnings Per Share Expected for CytomX Therapeutics, Inc. (CTMX) This Quarter-$0.39 Earnings Per Share Expected for CytomX Therapeutics, Inc. (CTMX) This Quarter
www.americanbankingnews.com - November 28 at 5:12 AM
ETFs with exposure to CytomX Therapeutics, Inc. : November 20, 2017ETFs with exposure to CytomX Therapeutics, Inc. : November 20, 2017
finance.yahoo.com - November 20 at 6:38 PM
CytomX Therapeutics, Inc. (CTMX) Receives Consensus Rating of "Hold" from BrokeragesCytomX Therapeutics, Inc. (CTMX) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 13 at 9:36 PM
CytomX Therapeutics, Inc. :CTMX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017CytomX Therapeutics, Inc. :CTMX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017
finance.yahoo.com - November 13 at 8:49 PM
CytomX Therapeutics, Inc. (CTMX) Expected to Announce Quarterly Sales of $10.70 MillionCytomX Therapeutics, Inc. (CTMX) Expected to Announce Quarterly Sales of $10.70 Million
www.americanbankingnews.com - November 11 at 7:00 AM
Zacks Investment Research Downgrades CytomX Therapeutics, Inc. (CTMX) to HoldZacks Investment Research Downgrades CytomX Therapeutics, Inc. (CTMX) to Hold
www.americanbankingnews.com - November 10 at 9:20 PM
Oppenheimer Holdings Comments on CytomX Therapeutics, Inc.s Q4 2017 Earnings (CTMX)Oppenheimer Holdings Comments on CytomX Therapeutics, Inc.'s Q4 2017 Earnings (CTMX)
www.americanbankingnews.com - November 10 at 9:04 AM
Wedbush Comments on CytomX Therapeutics, Inc.s FY2017 Earnings (CTMX)Wedbush Comments on CytomX Therapeutics, Inc.'s FY2017 Earnings (CTMX)
www.americanbankingnews.com - November 10 at 7:47 AM
FY2017 EPS Estimates for CytomX Therapeutics, Inc. Reduced by Analyst (CTMX)FY2017 EPS Estimates for CytomX Therapeutics, Inc. Reduced by Analyst (CTMX)
www.americanbankingnews.com - November 10 at 7:47 AM
FY2017 EPS Estimates for CytomX Therapeutics, Inc. Reduced by Analyst (CTMX)FY2017 EPS Estimates for CytomX Therapeutics, Inc. Reduced by Analyst (CTMX)
www.americanbankingnews.com - November 10 at 7:47 AM
-$0.42 EPS Expected for CytomX Therapeutics, Inc. (CTMX) This Quarter-$0.42 EPS Expected for CytomX Therapeutics, Inc. (CTMX) This Quarter
www.americanbankingnews.com - November 9 at 3:52 PM

SEC Filings

CytomX Therapeutics (NASDAQ:CTMX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

CytomX Therapeutics (NASDAQ:CTMX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

CytomX Therapeutics (NASDAQ CTMX) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.